We could not find any results for:
Make sure your spelling is correct or try broadening your search.
NOX-E36 bietet vielversprechende Entwicklungsmöglichkeiten für Augenkrankheiten mit einem hohen Bedarf an gut verträglichen Therapien mit antifibrotischer Wirkung Die antifibrotische...
NOX-E36 presents promising opportunity for development in eye diseases with a high need for well-tolerated therapies with anti-fibrotic effect Anti-fibrotic mode of action of NOX-E36 was...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.006 | 4.13793103448 | 0.145 | 0.153 | 0.1358 | 105842 | 0.1477107 | DE |
4 | 0.028 | 22.7642276423 | 0.123 | 0.18 | 0.123 | 722370 | 0.1489076 | DE |
12 | -0.009 | -5.625 | 0.16 | 0.18 | 0.1124 | 527923 | 0.14484808 | DE |
26 | -0.102 | -40.3162055336 | 0.253 | 0.26 | 0.1124 | 404481 | 0.15351795 | DE |
52 | -0.249 | -62.25 | 0.4 | 0.436 | 0.1124 | 637805 | 0.2444935 | DE |
156 | 0.1092 | 261.244019139 | 0.0418 | 5.98 | 0.0398 | 325497 | 0.34720291 | DE |
260 | 0.1092 | 261.244019139 | 0.0418 | 5.98 | 0.0398 | 325497 | 0.34720291 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions